TSR has shown to be of prognostic value in addition to the traditional prognostic markers which are implemented in standard clinical care, for example, TNM stage, receptor status and HER2 expression, in breast cancer with a robust inter-observer variability. This evidence concerns the gene ERBB2 and breast carcinoma.